13F Holdings
中文EN

IMUX IMMUNIC, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1280776 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-24.5%
TTM EPS YoY135.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-223.2%
ROA-144.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets23.4%
Debt / equity0.00x
Current ratio4.28x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-36.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$81.98M$80.05M$83.22M$71.25M$61.12M
SG&A expense$21.25M$18.01M$16.01M$15.26M$13.30M
Operating income-$103.23M-$98.05M-$99.22M-$119.49M-$91.67M
Income tax$0————
Net income-$97.17M-$100.51M-$93.61M-$120.41M-$92.94M
EBITDA-$103.06M-$97.92M-$99.11M-$119.41M-$91.58M
EPS (basic)-0.62-1.00-2.11-3.78-3.93
EPS (diluted)-0.62-1.00-2.11-3.78-3.93
Dividends declared per share0.000.000.000.000.00
Weighted avg. shares (diluted)155.69M100.17M44.32M31.82M23.65M
Banking
Provision for credit losses$497,000$234,000———
Balance sheet
Cash & equivalents$15.48M$35.67M$46.67M$106.75M$86.86M
Current assets$22.87M$39.33M$52.53M$125.86M$104.99M
PP&E, net$608,000$545,000$466,000$294,000$152,000
Goodwill———$0$32.97M
Total assets$24.05M$40.87M$54.30M$127.75M$139.10M
Current liabilities$30.62M$22.18M$24.73M$13.08M$11.40M
Total liabilities$30.73M$22.44M$25.37M$14.07M$11.98M
Shareholders' equity-$6.67M$18.43M$28.93M$113.68M$127.11M
Shares outstanding15.88M90.15M45.18M39.31M26.34M
Cash flow statement
Operating cash flow-$85.81M-$84.77M-$70.83M-$65.14M-$83.23M
Capital expenditure$161,000$264,000$334,000$112,000$67,000
Free cash flow-$85.97M-$85.03M-$71.16M-$65.26M-$83.30M
Investing cash flow-$161,000-$264,000$9.46M-$9.74M-$67,000
Financing cash flow$65.58M$74.54M$1.03M$95.76M$42.84M
Depreciation & amortization$168,000$134,000$111,000$77,000$85,000
Stock-based compensation$8.86M$8.53M$7.10M$7.93M$5.95M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.